Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.37 CAD | +1.28% | +4.41% | +464.29% |
May. 22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+464.29% | 128M | |
+66.44% | 62.86B | |
-1.02% | 41.38B | |
+45.72% | 40.38B | |
-8.93% | 27.64B | |
+13.42% | 26.46B | |
-22.88% | 18.9B | |
+3.91% | 12.67B | |
+24.07% | 12.27B | |
+27.65% | 12.07B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022